Home › Compare › UMTAF vs ABBV
UMTAF yields 58.82% · ABBV yields 3.06%● Live data
📍 UMTAF pulled ahead of the other in Year 1
Combined, UMTAF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of UMTAF + ABBV for your $10,000?
Genertec Universal Medical Group Company Limited, together with its subsidiaries, offers financing and advisory services in the People's Republic of China. It operates in two segments, Finance and Advisory and Hospital Group. The Finance and Advisory segment provides direct finance leasing; sale and leaseback; factoring; operating leases; and advisory services. The Hospital Group segment engages in the provision of medical services; hospital and healthcare management; and import and export trading businesses, as well as trading of medical-related goods. The company is also involved in the provision of medical technology; hospital digitalization, construction, and management services; property management; and medical consulting services. It serves patients, hospitals, medical equipment suppliers, and other public institutions. The company was formerly known as Universal Medical Financial & Technical Advisory Services Company Limited and changed its name to Genertec Universal Medical Group Company Limited in July 2018. Genertec Universal Medical Group Company Limited was founded in 1984 and is headquartered in Beijing, China.
Full UMTAF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.